Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Dec 23, 2021 6:24pm
161 Views
Post# 34259609

Fat gain in PLWH

Fat gain in PLWH

“Fat gain in patients receiving HIV treatment is alarming because these patients are already at risk of developing multiple cardiovascular disorders. Further increase in the visceral or vascular fat deposition could raise their risks of developing these complications much higher. The visceral fat deposition could lead to Non-Alcoholic Fatty Liver Disease or NAFLD. Other problems such as increased insulin resistance, obesity, and liver cancer may soon follow if proper interventions are not executed at the right time.

Weight gain associated with HIV drugs is widely recognized. However, HIV itself can also contribute to weight gain. The disease process can trigger the inflammatory pathway and cause the release of cytokines. Cytokines can increase fat production and deposition, which leads to weight gain in HIV patients. Moreover, fat metabolism pathways may also get disturbed directly due to the virus and, thus, the disease process leads to weight gain.

There are some medications available that can help you tackle HIV-related lipodystrophy. Tesamorelin, an FDA-approved growth hormone-releasing factor, and Metformin, a drug used in the treatment of Diabetes Mellitus, may help you reduce the lipodystrophy associated with HIV treatment.”

 

This was posted on imghealthclinic.com last Saturday, easy to understand, Tesamorelin was also mentioned. They have few clinics in Florida. THTX should target several similar clinics who are focusing on HIV care

for both their drugs. Let them sell it for you!

 

Will HIV Medicines Cause Changes To Your Fat And Stomach? 

<< Previous
Bullboard Posts
Next >>